The Importance of an NCI SPORE Grant

Jeffrey S. Weber, MD, PhD
Published Online: October 31, 2013
Jeffrey S. Weber, MD, PhD, medical oncologist, Department of Cutaneous Oncology, director, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, comments on the importance of a Specialized Programs of Research Excellence (SPORE) grant.

Clinical Pearls

  • A Specialized Programs of Research Excellence (SPORE) grant is given out by the NCI
  • SPORE grants bring together investigators from all different disciplines focused on one histology
  • As a part of the SPORE grant given to Moffitt Cancer Center, each project has preclinical laboratory pieces leading to a clinical trial
  • Two out of three SPORE projects at Moffitt currently have clinical trials ongoing


Related Articles
Checkpoint inhibition has demonstrated efficacy for the treatment of melanoma in several clinical trials. However, biomarkers to predict safety and efficacy of immunotherapies in individual melanoma patients are lacking.
Knowledge of genetic expression of melanocytic lesions significantly reduced the number of indeterminate diagnoses made by dermatopathologists.
Pembrolizumab (Keytruda) significantly improved progression-free survival (PFS) by over 43% compared with chemotherapy as a treatment for patients with metastatic melanoma who were refractory to ipilimumab (Yervoy).
Frontline treatment with nivolumab (Opdivo) significantly extended overall survival (OS) and progression-free survival (PFS) when compared with dacarbazine in patients with untreated BRAF wild-type advanced melanoma.
JTT Articles
Targeting Radiotherapy in the Liver: SIR-Spheres®
HPV Test With Genotyping Supplants Pap Test
External Resources

AJMC
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.